MD, with over 20-year experience in clinical development, 18 years within the pharmaceutical industry with special focus on rare diseases, plus 7 additional year leading proof of concept trials at the Experimental Therapeutic Branch of the NINDS, National Institute of Health. Previously at Eisai, PTC Therapeutics, Ultragenyx and currently Head of Development at Dyne Therapeutics
